Supriya Lifescience Limited — PPTs, 13-08-2026: Investor Presentation

Supriya Lifescience reported strong Q1 FY27 revenue growth of 31% YoY to ₹189.75 Cr. However, EBITDA declined 8% to ₹47.46 Cr, and Profit After Tax (PAT) fell 31% to ₹24.04 Cr, with margins contracting. Europe (44%) and Asia (34%) were key revenue contributors, while Anesthetic (48%) remained the largest therapy segment.

The company's strategy focuses on its backward-integrated model, covering 72% of Q1 revenue, to ensure supply security and cost competitiveness. It also emphasizes diversified global presence across 120+ countries, with 81% of Q1 revenue from exports. New R&D centers are driving API and formulation development, with a goal to add 3-4 APIs annually.

Recent developments include the FY26 launches of Cardio Vascular, ADHD, and Liquid Anesthetic products. The Lote facility secured its 4th USFDA approval. For FY27, two new molecules each are planned for launch in Anesthetic and ADHD segments.

Key Q1 FY27 financial metrics include: Revenue: ₹189.75 Cr (up 31% YoY), PAT: ₹24.04 Cr (down 31% YoY), EPS: ₹2.99, and EBITDA margin: 25.0%.

Management outlook points to expanding the global API customer base and accelerating regulatory filings in the EU and US. Significant capacity enhancement is underway, including a new vitamin product block, debottlenecking across production blocks, and a new production block at Lote. The company is also evaluating CMO/CDMO opportunities.